Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China
BackgroundCoronavirus Disease 2019 (COVID-19) is an emerging and rapidly evolving disease, with no recommended effective anti-coronavirus drug treatment. Traditional Chinese Patent Medicines (CPMs) have, however, been widely used to treat COVID-19 in China, and a number of clinical practice results...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-07-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2020.01066/full |
id |
doaj-2801f06a96db4fbfb8c57d2c704fc7a2 |
---|---|
record_format |
Article |
spelling |
doaj-2801f06a96db4fbfb8c57d2c704fc7a22020-11-25T03:28:13ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-07-011110.3389/fphar.2020.01066560114Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in ChinaWei Zhuang0Zheng Fan1Yanqi Chu2Haizheng Wang3Ying Yang4Li Wu5Nan Sun6Ge Sun7Yuqiao Shen8Xiaolan Lin9Guiming Guo10Shengyan Xi11Department of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing, ChinaDepartment of Clinical Pharmacy, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, ChinaDepartment of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing, ChinaDepartment of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing, ChinaDepartment of Clinical Pharmacy, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, ChinaDepartment of Pharmacy, Beijing Mentougou District Hospital of Traditional Chinese Medicine, Beijing, ChinaPharmacy Department, Beijing Mentougou Hospital, Beijing, ChinaDepartment of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing, ChinaPharmaceutical Department, Guangdong Hospital of Traditional Chinese Medicine, Guangzhou, ChinaDepartment of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing, ChinaDepartment of Clinical Pharmacy, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, ChinaDepartment of Traditional Chinese Medicine, School of Medicine, Xiamen University, Xiamen, ChinaBackgroundCoronavirus Disease 2019 (COVID-19) is an emerging and rapidly evolving disease, with no recommended effective anti-coronavirus drug treatment. Traditional Chinese Patent Medicines (CPMs) have, however, been widely used to treat COVID-19 in China, and a number of clinical practice results have shown them to have a significant role in its treatment. Consequently, numerous guidelines and expert consensus have recommended the use of CPMs to treat COVID-19.Aim of the StudyThe objectives of this review are to provide up-to-date information on the pharmacology and clinical research on CPMs in the treatment of COVID-19, discuss the research findings, and to better guide clinical application and scientific research on CPMs in the treatment of COVID-19.MethodsThe frequencies of CPM recommendations by guidelines and expert consensus for treatment of COVID-19 in China were ranked. This report identifies the top 10 CPMs, which include Huoxiang Zhengqi capsule (HXZQC), Lianhua Qingwen capsule (LHQWC), Jinhua Qinggan granule (JHQGG), Shufeng Jiedu capsule (SFJDC), Tanreqing injection (TRQI), Xiyanping injection (XYPI), Xuebijing injection (XBJI), Shenfu injection (SFI), Shengmai injection (SMI), and Angong Niuhuang pill (AGNHP). Relevant studies from 2000 to 2020 on these top 10 CPMs, covering usage, dosage, mechanism, curative effect, and precautions, were collected from pharmacopoeia, reports, and theses via library and digital databases (including PubMed, CNKI, Google Scholar, Web of Science, and Elsevier).ResultsThe properties of the top 10 CPMs included antiviral, antibacterial, anti-inflammatory, antipyretic and analgesic, anti-acute lung injury, anti-shock, immune regulation, and enhancement of pulmonary function. In addition, clinical research results and Chinese treatment data showed that the CPMs had good therapeutic efficacy in the treatment of COVID-19, and adverse reactions were minimal.ConclusionsKnowledge of the characteristics of the top 10 CPMs and precautions that should be taken may help clinicians to rationally improve therapeutic efficacy, and promote the role of Chinese Medicine in the control of the COVID-19 global epidemic.https://www.frontiersin.org/article/10.3389/fphar.2020.01066/fullCOVID-19Chinese Patent Medicinespharmacological actionclinical applicationTraditional Chinese Medicine |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Wei Zhuang Zheng Fan Yanqi Chu Haizheng Wang Ying Yang Li Wu Nan Sun Ge Sun Yuqiao Shen Xiaolan Lin Guiming Guo Shengyan Xi |
spellingShingle |
Wei Zhuang Zheng Fan Yanqi Chu Haizheng Wang Ying Yang Li Wu Nan Sun Ge Sun Yuqiao Shen Xiaolan Lin Guiming Guo Shengyan Xi Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China Frontiers in Pharmacology COVID-19 Chinese Patent Medicines pharmacological action clinical application Traditional Chinese Medicine |
author_facet |
Wei Zhuang Zheng Fan Yanqi Chu Haizheng Wang Ying Yang Li Wu Nan Sun Ge Sun Yuqiao Shen Xiaolan Lin Guiming Guo Shengyan Xi |
author_sort |
Wei Zhuang |
title |
Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China |
title_short |
Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China |
title_full |
Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China |
title_fullStr |
Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China |
title_full_unstemmed |
Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China |
title_sort |
chinese patent medicines in the treatment of coronavirus disease 2019 (covid-19) in china |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2020-07-01 |
description |
BackgroundCoronavirus Disease 2019 (COVID-19) is an emerging and rapidly evolving disease, with no recommended effective anti-coronavirus drug treatment. Traditional Chinese Patent Medicines (CPMs) have, however, been widely used to treat COVID-19 in China, and a number of clinical practice results have shown them to have a significant role in its treatment. Consequently, numerous guidelines and expert consensus have recommended the use of CPMs to treat COVID-19.Aim of the StudyThe objectives of this review are to provide up-to-date information on the pharmacology and clinical research on CPMs in the treatment of COVID-19, discuss the research findings, and to better guide clinical application and scientific research on CPMs in the treatment of COVID-19.MethodsThe frequencies of CPM recommendations by guidelines and expert consensus for treatment of COVID-19 in China were ranked. This report identifies the top 10 CPMs, which include Huoxiang Zhengqi capsule (HXZQC), Lianhua Qingwen capsule (LHQWC), Jinhua Qinggan granule (JHQGG), Shufeng Jiedu capsule (SFJDC), Tanreqing injection (TRQI), Xiyanping injection (XYPI), Xuebijing injection (XBJI), Shenfu injection (SFI), Shengmai injection (SMI), and Angong Niuhuang pill (AGNHP). Relevant studies from 2000 to 2020 on these top 10 CPMs, covering usage, dosage, mechanism, curative effect, and precautions, were collected from pharmacopoeia, reports, and theses via library and digital databases (including PubMed, CNKI, Google Scholar, Web of Science, and Elsevier).ResultsThe properties of the top 10 CPMs included antiviral, antibacterial, anti-inflammatory, antipyretic and analgesic, anti-acute lung injury, anti-shock, immune regulation, and enhancement of pulmonary function. In addition, clinical research results and Chinese treatment data showed that the CPMs had good therapeutic efficacy in the treatment of COVID-19, and adverse reactions were minimal.ConclusionsKnowledge of the characteristics of the top 10 CPMs and precautions that should be taken may help clinicians to rationally improve therapeutic efficacy, and promote the role of Chinese Medicine in the control of the COVID-19 global epidemic. |
topic |
COVID-19 Chinese Patent Medicines pharmacological action clinical application Traditional Chinese Medicine |
url |
https://www.frontiersin.org/article/10.3389/fphar.2020.01066/full |
work_keys_str_mv |
AT weizhuang chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina AT zhengfan chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina AT yanqichu chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina AT haizhengwang chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina AT yingyang chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina AT liwu chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina AT nansun chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina AT gesun chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina AT yuqiaoshen chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina AT xiaolanlin chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina AT guimingguo chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina AT shengyanxi chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina |
_version_ |
1724585648013180928 |